DZ1677A1 - Procédé pour la préparation de composés pour le traitement des troubles neuro-dégénératifs. - Google Patents

Procédé pour la préparation de composés pour le traitement des troubles neuro-dégénératifs.

Info

Publication number
DZ1677A1
DZ1677A1 DZ930038A DZ930038A DZ1677A1 DZ 1677 A1 DZ1677 A1 DZ 1677A1 DZ 930038 A DZ930038 A DZ 930038A DZ 930038 A DZ930038 A DZ 930038A DZ 1677 A1 DZ1677 A1 DZ 1677A1
Authority
DZ
Algeria
Prior art keywords
treatment
neurodegenerative disorders
compounds
preparation
pyridineethanamine
Prior art date
Application number
DZ930038A
Other languages
English (en)
Original Assignee
Fisons Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Fisons Corp filed Critical Fisons Corp
Application granted granted Critical
Publication of DZ1677A1 publication Critical patent/DZ1677A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DZ930038A 1992-04-03 1993-04-03 Procédé pour la préparation de composés pour le traitement des troubles neuro-dégénératifs. DZ1677A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties

Publications (1)

Publication Number Publication Date
DZ1677A1 true DZ1677A1 (fr) 2002-02-17

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ930038A DZ1677A1 (fr) 1992-04-03 1993-04-03 Procédé pour la préparation de composés pour le traitement des troubles neuro-dégénératifs.

Country Status (29)

Country Link
EP (1) EP0633879B1 (fr)
JP (2) JP3120810B2 (fr)
KR (1) KR100259567B1 (fr)
CN (1) CN1044367C (fr)
AT (1) ATE163925T1 (fr)
AU (2) AU3897693A (fr)
CA (1) CA2133427C (fr)
CZ (1) CZ288519B6 (fr)
DE (1) DE69317411T2 (fr)
DK (1) DK0633879T3 (fr)
DZ (1) DZ1677A1 (fr)
ES (1) ES2115055T3 (fr)
FI (1) FI105025B (fr)
HK (1) HK1009331A1 (fr)
HU (1) HU211529A9 (fr)
IL (1) IL105276A (fr)
MA (1) MA22866A1 (fr)
MX (1) MX9301935A (fr)
MY (1) MY110149A (fr)
NO (1) NO302170B1 (fr)
NZ (1) NZ251384A (fr)
PL (1) PL180014B1 (fr)
RU (1) RU2128650C1 (fr)
SG (1) SG47948A1 (fr)
SK (1) SK281258B6 (fr)
TW (1) TW282455B (fr)
UA (1) UA29437C2 (fr)
WO (1) WO1993020052A1 (fr)
ZA (1) ZA932415B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
EP0356035B1 (fr) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylalkyl-amines et -amides à activité anticonvulsive et neuroprotectrice
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (fr) * 2005-08-10 2007-02-15 Astrazeneca Ab Utilisation therapeutique
CA2748235A1 (fr) * 2008-12-24 2010-07-01 Astrazeneca Ab Composes d'ethanamine et leur application pour le traitement de la depression
EP2791352A1 (fr) 2011-12-14 2014-10-22 Astrazeneca AB Diagnostic de gabr-a2
TR201909632T4 (tr) * 2013-11-05 2019-07-22 Astrazeneca Ab Nmda antagonisti ön ilaçları.
US20230190719A1 (en) * 2020-06-23 2023-06-22 Biohaven Therapeutics Ltd. Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356035B1 (fr) * 1988-08-12 1996-03-13 Astra Aktiebolag Arylalkyl-amines et -amides à activité anticonvulsive et neuroprotectrice

Also Published As

Publication number Publication date
FI105025B (fi) 2000-05-31
JPH07505385A (ja) 1995-06-15
IL105276A (en) 1997-06-10
DE69317411D1 (de) 1998-04-16
ZA932415B (en) 1993-10-22
EP0633879B1 (fr) 1998-03-11
KR100259567B1 (ko) 2000-07-01
NO943645L (no) 1994-11-16
HU211529A9 (en) 1995-11-28
FI944546A (fi) 1994-09-30
DK0633879T3 (da) 1998-09-28
AU3897693A (en) 1993-11-08
CN1044367C (zh) 1999-07-28
MX9301935A (es) 1994-08-31
CA2133427A1 (fr) 1993-10-14
NO943645D0 (no) 1994-09-30
AU7545696A (en) 1997-02-13
TW282455B (fr) 1996-08-01
WO1993020052A1 (fr) 1993-10-14
RU94042465A (ru) 1996-07-20
CN1081669A (zh) 1994-02-09
HK1009331A1 (en) 1999-05-28
DE69317411T2 (de) 1998-07-30
FI944546A0 (fi) 1994-09-30
MA22866A1 (fr) 1993-12-31
UA29437C2 (uk) 2000-11-15
AU705419B2 (en) 1999-05-20
NO302170B1 (no) 1998-02-02
SK281258B6 (sk) 2001-01-18
JP2000319259A (ja) 2000-11-21
EP0633879A1 (fr) 1995-01-18
CZ288519B6 (cs) 2001-07-11
ES2115055T3 (es) 1998-06-16
ATE163925T1 (de) 1998-03-15
CA2133427C (fr) 2003-06-10
IL105276A0 (en) 1993-08-18
PL180014B1 (pl) 2000-11-30
SG47948A1 (en) 1998-04-17
MY110149A (en) 1998-02-28
SK117794A3 (en) 1995-05-10
CZ240994A3 (en) 1995-12-13
NZ251384A (en) 1996-10-28
JP3120810B2 (ja) 2000-12-25
RU2128650C1 (ru) 1999-04-10

Similar Documents

Publication Publication Date Title
EG20218A (en) Process for preparing of substituted 3 aminoquinuclidines
DZ2114A1 (fr) Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.
DZ2186A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.
FR2689515B1 (fr) Procédé pour la préparation des pigments composites.
FR2707087B1 (fr) Nouveau procédé de préparation de l'ergothionéine.
FI102177B1 (fi) Menetelmä uusien terapeuttisesti aktiivisten kromaani- ja tiokromaanijohdannaisten valmistamiseksi ja välituotteet
DZ1677A1 (fr) Procédé pour la préparation de composés pour le traitement des troubles neuro-dégénératifs.
HUT45960A (en) Process for producing 2,4,5-trisubstituted derivatives of phenol of antiflogistic activity
FI93117C (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 9-aminotetrahydroakridiinijohdannaisten valmistamiseksi
MA22495A1 (fr) Derives d'amidinophenylalanine, procede pour leur preparation et leur utilisation
DZ1946A1 (fr) Procédé pour la préparation de supports.
GR3006366T3 (fr)
FR2687681B1 (fr) Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
OA07002A (fr) Dérivé de la pyrrolidine, sa préparation et ses utilisations thérapeutiques pour le traitement de l'insuffisance cérébrale.
FI885560A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
FR2721598B1 (fr) Procédé de préparation de catalyseurs d'ammoxydation.
FR2708266B1 (fr) Procédé de préparation d'alcanesulfonamides.
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
FR2715656B1 (fr) Procédé de préparation d'anhydride citraconique.
MA22278A1 (fr) Procede pour le traitement de troubles respiratoires
FR2658419B1 (fr) Medicament pour le traitement de la dermatite.
FR2695388B1 (fr) Dérivés de 1,3,4-benzotriazépin-5(4H)-one et procédé pour leur préparation.
EP0583136A3 (en) Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders
BR9714184A (pt) Utilização de bonzoillquil-1,2,3,6-tetraidropiridinas
FR2699919B1 (fr) Dérivés d'imidazole, leur procédé de préparation et leur application en thérapeutique.